Skip to content
Parakho

Supriya Lifescience Ltd

NSE SUPRIYABSE 543434supriyalifescience.comInvestor relations

Q1 FY27, unaudited

Revenue
₹189.75 Cr
Profit after tax
₹24.04 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations189.75+30.79%827.88
Other income2.65−0.97%11.49
Total income192.40+30.22%839.36
Employee benefit expense28.49+25.57%96.68
Finance costs0.37−26.95%1.89
Depreciation & amortisation8.94+38.58%28.41
Total expenses151.60+51.10%564.13
Profit before tax40.79−13.96%274.78
Tax expense16.75+32.70%65.66
Profit after tax24.04−30.89%209.12
Total comprehensive income24.69−28.59%209.02
Earnings per share
Earnings per share, basic₹2.99₹25.98
Earnings per share, diluted₹2.99₹25.98

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Supriya Lifescience reported Q1 FY'27 revenue of Rs. 190 crores, up 31% year-on-year, while EBITDA fell 8.1% to Rs. 47 crores with margins at 25%, which management attributed to a temporary water shortage near its Lote plant and a one-time solar power policy change. Management said around Rs. 35 crores of sales were deferred due to the water issue and Rs. 8 crores of EBITDA impact came from higher fuel and power costs. Management reiterated its target of approaching Rs. 1,000 crores in revenue for FY'27 and an EBITDA margin range of 33% to 35%, while discussing Ambernath facility launches, the Patalganga land project, and an ongoing customs matter involving an export authorization lapse.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.